Document is current
Any future updates will be listed below
-
Authors
Hanna, Ann
Nixon, Mellissa J.
Estrada, M. Valeria
Sanchez, Violeta
Sheng, Quanhu
Opalenik, Susan R.
Toren, Abigail L.
Bauer, Joshua
Owens, Phillip
Mason, Frank M.
Cook, Rebecca S.
Sanders, Melinda E.
Arteaga, Carlos L.
Balko, Justin M. http://orcid.org/0000-0002-4263-5974
-
Funding
Funding for this research was provided by:
Susan G. Komen for the Cure (CCR14299052)
National Cancer Institute (R00CA181491, 2P50CA098131-17, R50CA211206)
U.S. Department of Defense (BC170037)
Vanderbilt-Ingram Cancer Center (CA68485)
- License Information
-
More Information
Article History
Received: 6 November 2021
Accepted: 28 June 2022
First Online: 18 July 2022
Declarations
:
: Not applicable; this work includes no primary patient studies.
: Not applicable.
: JMB receives research support from Genentech/Roche, Bristol Myers Squibb, and Incyte Corporation, has received consulting/expert witness fees from Novartis, and is an inventor on provisional patents regarding immunotherapy targets and biomarkers in cancer.CLA serves or has served in a scientific advisory role to Novartis, Lilly, Merck, TAIHO Oncology, Daichii Sankyo, AstraZeneca, OrigiMed, Immunomedics, Sanofi, Athenex, Arvinas and the Susan G. Komen Foundation. He has received grant support from Pfizer, Lilly, and Takeda. He holds minor stock options in Provista. None of these activities have any relationship to the research in this manuscript.
